Nutex Health, Inc. (NUTX) Revenue History
Annual and quarterly revenue from 2011 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
NUTX Revenue Growth
Revenue Breakdown (FY 2024)
NUTX's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
NUTX Revenue Analysis (2011–2025)
As of May 8, 2026, Nutex Health, Inc. (NUTX) generated trailing twelve-month (TTM) revenue of $880.0 million, reflecting modest growth of +2.2% year-over-year. The most recent quarter (Q1 2026) recorded $216.5 million in revenue, up 42.7% sequentially.
Looking at the longer-term picture, NUTX's 5-year compound annual growth rate (CAGR) stands at +26.1%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $875.3 million in 2025, representing a new all-time high.
Revenue diversification analysis shows NUTX's business is primarily driven by Hospital Division (100%). With over half of revenue concentrated in Hospital Division, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ADUS (+19.6% YoY), AMSF (+7.8% YoY), and UHS (+10.4% YoY), NUTX has underperformed the peer group in terms of revenue growth. Compare NUTX vs ADUS →
NUTX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| NUTXCurrent | $880M | +2.2% | +26.1% | 31.5% | |
 ADUS | $1.4B | +19.6% | +13.2% | 9.7% | |
 AMSF | $317M | +7.8% | -1.3% | 18.6% | |
 UHS | $17.4B | +10.4% | +8.5% | 11.5% | |
 THC | $21.3B | +4.6% | +3.9% | 16.1% | |
 CYH | $12.5B | +69.8% | +1.2% | -79.4% |
NUTX Historical Revenue Data (2011–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $875.3M | +82.4% | $444.3M | 50.8% | $275.6M | 31.5% |
| 2024 | $479.9M | +93.8% | $196.3M | 40.9% | $130.6M | 27.2% |
| 2023 | $247.6M | +12.9% | $34.8M | 14.0% | $-31,773,748 | -12.8% |
| 2022 | $219.3M | -33.9% | $15.4M | 7.0% | $-406,599,154 | -185.4% |
| 2021 | $331.5M | +21.0% | $179.3M | 54.1% | $170.3M | 51.4% |
| 2020 | $274.0M | +182.3% | $157.6M | 57.5% | $153.2M | 55.9% |
| 2019 | $97.1M | +106120.8% | $97.1M | 100.0% | $34.7M | 35.8% |
| 2018 | $91K | +70.3% | $29K | 31.8% | $-1,830,561 | -2003.4% |
| 2017 | $54K | - | $-510,720 | -952.0% | $-5,692,920 | -10611.8% |
| 2016 | $0 | - | $-473 | - | $-448,600 | - |
See NUTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NUTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NUTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonNUTX — Frequently Asked Questions
Quick answers to the most common questions about buying NUTX stock.
Is NUTX's revenue growth accelerating or slowing?
NUTX revenue growth slowed to +2.2%, below the 5-year CAGR of +26.1%. TTM revenue is $880M. The deceleration marks a shift from historical growth rates.
What is NUTX's long-term revenue growth rate?
Nutex Health, Inc.'s 5-year revenue CAGR of +26.1% reflects the variable expansion pattern. Current YoY growth of +2.2% is near this long-term average.
How is NUTX's revenue distributed by segment?
NUTX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2011-2025 are available for download. Segment mix reveals concentration and diversification trends.